3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
64
Neoplasm Metastasis
14
Brain Neoplasms
10
Neoplasms
9
Endometrial Neoplasms
8
Prostatic Neoplasms
7
Glioblastoma
7
Ovarian Neoplasms
6
Triple Negative Breast Neoplasms
5
Glioma
5
Sarcoma
3
Recurrence
3
Neoplasms by Site
3
Meningioma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Osteosarcoma
2
Liposarcoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Interventions
etoposide phosphate
1
elacestrant
1
binimetinib
1
abemaciclib
1
XENP 1595
1
Tissue Banks
1
Radiosurgery
1
RAD1901
1
PF-07284890
1
Midazolam
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Diseases
×
abemaciclib
×
1 year
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled